 |
|
Regression of a Subfoveal Choroidal Metastasis of Colorectal Carcinoma After Intravitreous Bevacizumab Treatment
Irene C. Kuo, MD;
Julia A. Haller, MD;
Roque Maffrand, MD;
Ruben H. Sambuelli, MD, PhD;
Victor E. Reviglio, MD, PhD
Arch Ophthalmol. 2008;126(9):1311-1313.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In 2004, bevacizumab (Avastin; Genentech, Inc, South San Francisco, California) received approval by the US Food and Drug Administration for treatment of metastatic carcinoma of the colon or rectum. Approval of bevacizumab for treatment of select cases of nonsquamous, non–small cell lung cancer followed in 2006. Bevacizumab is the first Food and Drug Administration–approved biological therapy designed to inhibit tumor angiogenesis. It targets all isoforms of vascular endothelial growth factor, a diffusible cytokine that promotes angiogenesis and vascular permeability.
Off-label use of intravitreous bevacizumab for potentially blinding ocular neovascular conditions has grown since the first case report in neovascular age-related macular degeneration.1 Its off-label intravitreous use has been described for choroidal neovascularization in pathological myopia,2-3 proliferative diabetic retinopathy,4-7 and neovascular glaucoma.8
We herein describe a patient who was successfully . . . [Full Text of this Article] Report of a Case
Comment
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Lutein/Zeaxanthin—Reply
John Paul SanGiovanni
Arch Ophthalmol. 2008;126(9):1313-1314.
EXTRACT
| FULL TEXT
|
